Modern neuro-oncology classifies tumors, like diffuse gliomas, by markers such as IDH mutation, 1p/19q co-deletion, methylguanine-DNA methyltransferase (MGMT) status, and others; features that not only predict prognosis but also influence how a tumor interacts with the brain [48]. This evidence concerns the gene MGMT and neoplasm.